Inhibition of Huntington synthesis by antisense oligodeoxynucleotides

The Huntington disease gone encodes the protein huntington, which is widely expressed during embryonic development and in mature tissues. In order to elucidate the physiological function of huntington, which so far is unknown, we intend to study the effect of antisense down-regulated huntington expression. We have found an inhibiting effect of a phosphorothioated oligodeoxynucleotide (PS-ODN) added to the culture medium of embryonic teratocarcinoma cells (NT2) and postmitotic neurons (NT2N neurons) differentiated from the NT2 cells. Specific inhibition of expression of endogenous huntington was achieved in NT2N neurons in the concentration range of 1-5 microM PS-ODN, whereas no inhibition was obtained in NT2 cells. We describe in detail the selection of the target sequence for the antisense oligo and the uptake, intracellular distribution, and stability of the antisense PS-ODN in the two cell types. Antisense down-regulation of huntington in this model of human neurons represents a suitable approach to study its normal function.

CAG repeat expansion in autosomal dominant pure spastic paraplegia linked to chromosome 2p21-p24

CAG repeat expansions have been identified as the disease-causing dynamic mutations in the coding regions of genes in several dominantly inherited neurodegenerative disorders, including spinobulbar muscular atrophy, Huntington's disease, dentatorubral-pallidoluysian atrophy, spinocerebellar ataxia type 1, 2 and 6 and Machado-Joseph disease. The CAG repeat expansions are translated to elongated polyglutamine tracts and an increased size of the polyglutamine tract correlates with anticipation, the cardinal feature, seen in all these diseases. Autosomal dominant pure spastic peraplegia (ADPSP) is a degenerative disorder of the central motor system clinically characterized by slowly progressive and unremitting spasticity of the legs, hyperreflexia and Babinski's sign. Like the established CAG repeat diseases ADPSP is characterized by both inter- and intrafamilial variation and anticipation. Using the Repeat Expansion Detection (RED) method, we have analyzed 21 affected individuals from six Danish families with the disease linked to chromosome 2p21-p24. We found that 20 of 21 affected individuals showed CAG repeat expansions versus two of 21 healthy spouses, demonstrating a strongly statistically significant association between the occurrence of the repeat expansion and the disease (Fisher's test, P < 10(-5)) suggesting that a CAG repeat expansion is involved presumably as a dynamic mutation in ADPSP linked to chromosome 2p21-p24. The size of the expansion is estimated to be > or = 60 CAG repeat copies in the affected individuals. The CAG repeat expansion is very likely translated and expressed as indicated by the detection of a polyglutamine-containing protein in an ADPSP patient.

Interleukin-6 autoantibodies: possible biological and clinical significance

The pleiotropic cytokines, interleukin (IL)-1 alpha, type I interferons and IL-6 also act on cells involved in antibody production. Somehow the immunologic tolerance to these cytokines is often spontaneously broken--even in healthy individuals. Thus, relatively high concentrations of high affinity IgG antibodies against IL-1 alpha and IL-6 frequently occur in the circulation of healthy adults. The autoantibodies specifically antagonize the respective cytokines in vitro. Thermodynamic estimations strongly suggest that autoimmunity can play a significant role in the regulation of certain cytokines. In the light of IL-6 autoantibodies the possible biological and clinical significance of cytokine autoimmunity is discussed.

Influence of interleukin-6 (IL-6) autoantibodies on IL-6 binding to cellular receptors

Neutralizing autoantibodies to interleukin-6 (aAb-IL-6) have been reported in healthy individuals, in patients with autoimmune diseases, and in pharmaceutically prepared pooled IgG (IVIg). We investigated the ability of aAb-IL-6 derived from IVIg to interfere with IL-6 binding to the undifferentiated monocytic cell line U-937. High-affinity aAb-IL-6, primarily of the IgG1 subclass, constituted approximately 1:10(6) of the total IgG in IVIg preparations. IL-6 binding to cellular receptors was strongly inhibited by one class of aAb-IL-6. These antibodies recognized epitope(s) on IL-6 essential for the binding of IL-6 to the alpha subunit of the IL-6 receptor (IL-6R). Another class of aAb-IL-6 recognized epitope(s) on IL-6, which is not essential for the binding to IL-6R but nevertheless important for the formation of high-affinity cellular IL-6 binding. These antibodies presumably interfered with the association of IL-6 receptor beta chains (gp130) with IL-6/IL-6R complexes, implicating that small IL-6/aAb-IL-6 immune complexes bound saturably (low affinity/high capacity) to cellular IL-6 receptors. There was no detectable binding of IL-6 through aAb-IL-6 and Fc receptors on U-937, and IVIg had no direct IL-6 receptor antagonizing activity. Dissociation kinetics of IL-6/aAb-IL-6 complexes at 37 degrees C revealed that IL-6 was liberated from 75% of the aAb-IL-6 with a half-time (t/2) approximately 4 h but bound almost irreversibly to the remaining aAb-IL-6 (t/2 > 20 h). Cellular IL-6 uptake and degradation was suppressed by aAb-IL-6. Taken together, the data suggest that loss of immunologic tolerance against IL-6 might be a novel physiological mechanism by which IL-6 activities are effectively attenuated. Finally, binding of IL-6 in complex with IgG1 aAb-IL-6 on cells expressing IL-6 receptors implicates that such cells could be targets of antibody-dependent immunological reactions, including cytotoxic reactions.

Sex- and age-dependency of IgG auto-antibodies against IL-1 alpha in healthy humans

Naturally occurring anti-interleukin (IL)-1 alpha IgG antibodies (Ab-IL-1 alpha) were measured in sera of 466 healthy Danish blood donors. Ab-IL-1 alpha bound IL-1 alpha with exceptionally high affinity (Kd: 10(-11) M) and neutralized both cell-associated and extracellular IL-1 alpha but not IL-1 beta or IL-1 receptor antagonist. More than 80% of the saturable binding of rIL-1 alpha to serum was to Ab-IL-1 alpha, suggesting that these antibodies are the quantitatively most important IL-1 alpha-binding components in serum. Judged by second antibody precipitation assay, the prevalence of Ab-IL-1 alpha varied between 30% and 75% and correlated positively with age (P = 0.037). The binding capacity of serum also increased with age. Although men were more frequently positive than women (P < 0.001), there were no sex- or age-dependent alterations in the average affinities of the antibodies. Free IL-1 alpha-like molecules were generally not detected in these sera. However, acid treatment showed that 25% of Ab-IL-1 alpha-positive sera contained low amounts of IL-1 alpha-Ab-IL-1 alpha immune complexes. IgG4 represented the main IgG isotype, whereas IgG3 Ab-IL-1 alpha were undetectable. The relative amounts of IgG4 Ab-IL-1 alpha increased while IgG2-and IgG1 Ab-IL-1 alpha decreased in elderly individuals. The presence in normal individuals and the lack of affinity maturation with age suggest that Ab-IL-1 alpha may be regulatory natural auto-antibodies perhaps coded by germline genes.

Specific binding of interleukin 1 (IL-1) beta and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I

Molecules that bind recombinant interleukin 1 (rIL-1) beta and rIL-1 receptor antagonist (rIL-1ra) with high affinity were detected in sera of healthy individuals. rIL-1 beta bound with dissociation constants in the nanomolar range, and the serum binding capacity was 40-50 ng/ml. rIL-1ra bound with 30 times higher affinity, and the serum binding capacity was 0.7-1 ng/ml. Rabbit antibodies against the recombinant-derived extracellular part of human IL-1 receptor type I (rsIL-1RI) selectively inhibited the binding of 125I-rIL-1ra to the serum factor(s). Almost 70% of the high-affinity IL-1ra-binding capacity was recovered after immunosorption with these antibodies. Binding of 125I-rIL-1ra to rsIL-1RI was blocked by rIL-1 alpha and by rIL-1 beta. In contrast, the purified rIL-1ra-binding factor (IL-1raBF) failed to bind rIL-1 alpha and rIL-1 beta. Gel filtration chromatography indicated a 1:1 binding of rIL-1 beta and rIL-1ra to their respective serum factors. The apparent molecular size of both serum factors was 70-80 kDa. Using SDS-PAGE and autoradiography, IL-1raBF had a molecular size of 60 kDa. We conclude that IL-1raBF, a serum factor which selectively and with high affinity binds IL-1ra (Kd = 70 pM), is related to or identical with a soluble form of IL-1RI. If upregulated during disease, IL-1raBF may constitute yet another level of natural regulation of IL-1 bioactivities.